Henry Schein, Inc.
HSIC Healthcare Medical - Distribution NASDAQ
$77.60
$-2.57 (-3.21%)
Open: $79.27 | High: $79.29 | Low: $76.89 | Prev Close: $80.17
Market Cap: $9.14B
Volume: 1.7M | Avg: 1.4M
Last updated: March 09, 2026 at 02:02 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 492
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 23.73 |
| P/B Ratio | 2.81 |
| P/S Ratio | 0.69 |
| EPS | $3.27 |
| Beta | 0.85 |
| Shares Outstanding | 117.72M |
| 52-Week High | $89.29 |
| 52-Week Low | $60.56 |
| SMA 50 | $78.10 |
| SMA 200 | $71.93 |
| Next Earnings | May 04, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 29.1% |
| Operating Margin | 5.8% |
| Net Margin | 3.0% |
| ROE | 11.9% |
| ROA | 3.5% |
| Debt/Equity | 1.14 |
| Current Ratio | 1.38 |
| Quick Ratio | 0.76 |
Balance Sheet
| Total Assets | $11.21B |
| Total Liabilities | $6.42B |
| Total Equity | $3.25B |
|
|
|
| Cash | $156.00M |
| Total Debt | $3.69B |
| Net Debt | $3.53B |
Income Statement
| Revenue | $13.18B |
| Gross Profit | $3.84B |
| Operating Income | $758.00M |
| Net Income | $398.00M |
|
|
|
| EBITDA | $1.01B |
| Revenue/Share | $112.34 |
Cash Flow
| Operating CF | $712.00M |
| CapEx | $139.00M |
| Free Cash Flow | $573.00M |
|
|
|
| Book Value/Share | $40.85 |
| Tangible Book/Share | $-3.72 |
| Equity/Share | $27.65 |
Technical Indicators
| RSI (14) | 46.40 Neutral |
| MACD |
0.59
Signal: 0.92
|
| Volatility | 35.69% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +8.02% |
| Sharpe Ratio | 0.23 Fair |
| Volatility (Ann.) | 28.95% Moderate |
| HSIC (1Y) | +8.02% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -5.02% |
Sector Comparison (Healthcare)
| Metric | HSIC | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 23.73 | 27.73 | 42% |
| P/B Ratio | 2.81 | -19.58 | 49% |
| ROE (%) | 11.92% | -9.51% | 45% |
| Net Margin (%) | 3.02% | 9.44% | 26% |
| Stock Score | 492 | 544.0 | 19% |
| 1Y Return (%) | +8.02 % | +8.15 % | 60% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HSIC | $77.60 | $79.77 | $80.47 | $80.22 | $78.13 | $71.93 | 46.40 | 0.59 | 35.69% | 334651 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the HSIC stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| HSIC | Henry Schein: Still A Buy - But Caution Is Warranted | Neutral | seekingalpha.com | Read More |
| HSIC | Henry Schein, Inc. (HSIC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| HSIC | Henry Schein One Unveils the Next Era of Dentrix Ascend for DSOs and Growth-Focused Practices | Positive | businesswire.com | Read More |
| HSIC | Dimensional Fund Advisors LP Boosts Stake in Henry Schein, Inc. $HSIC | Neutral | defenseworld.net | Read More |
| HSIC | Henry Schein, Inc. (HSIC) Presents at Leerink Global Healthcare Conference 2026 Transcript | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for HSIC
Company Information
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
| CEO | Andrea Albertini |
| Employees | 25000 |
| Country | US |
| IPO Date | 1995-11-03 |
| Exchange | NASDAQ |
| Website | https://www.henryschein.com |
| Sector | Healthcare |
| Industry | Medical - Distribution |
Similar Stocks (Healthcare - Medical - Distribution)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category